Phuong Trinh
Infectious Disease · Silver Spring, MDNPI 1679536486
Payments from drug & device makers
Across 855 payments — averaging $229.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$97K
- Gilead$91K
- AbbVie$1K
- Merck$923
- Insmed, Inc.$762
- Adaptive Biotechnologies Corporation$757
- plus $3K from 16 others
What the payments were for
- Consulting fees$10,2705%
- Speaking & faculty fees$157,94981%
- Travel & lodging$6,1363%
- Food & beverage$21,25811%
- Education$3940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 217 | $97,448 |
| Gilead | 406 | $91,366 |
| AbbVie(2 entities) | 47 | $1,423 |
| Merck | 59 | $923 |
| Insmed, Inc. | 24 | $762 |
| Adaptive Biotechnologies Corporation | 3 | $757 |
| Johnson & Johnson(2 entities) | 24 | $621 |
| Janssen Products, LP | 6 | $540 |
| Theratechnologies Inc. | 17 | $540 |
| La Jolla Pharmaceutical Company | 14 | $333 |
| Cipla USA Inc. | 2 | $278 |
| AstraZeneca | 3 | $234 |
| Paratek Pharmaceuticals, Inc. | 11 | $210 |
| Napo Pharmaceuticals Inc | 8 | $187 |
| Shionogi Inc | 5 | $115 |
| Comsort, Inc | 1 | $100 |
| Novartis | 2 | $53 |
| Melinta Therapeutics, LLC | 2 | $32 |
| Janssen Scientific Affairs, LLC | 1 | $25 |
| Pfizer | 1 | $24 |
| Mylan Institutional Inc. | 1 | $21 |
| Fortovia Therapeutics, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$196,007 in reported general payments places this provider in the 85th percentile of 289 infectious disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 328 | $1,431,296 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 160 | $715,132 |
| DovatoDolutegravir Sodium/Lamivudine | 101 | $293,263 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 20 | $93,402 |
| DescovyEmtricitabine/Tenofov Alafenam | 37 | $89,186 |
| PrezcobixDarunavir/Cobicistat | 20 | $61,123 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 11 | $40,561 |
| TivicayDolutegravir Sodium | 15 | $33,412 |
| Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df | 22 | $10,241 |
| Atorvastatin Calcium | 104 | $1,156 |
| Rifampin | 22 | $975 |
| Levothyroxine Sodium | 20 | $285 |
| Metformin Hcl ErMetformin Hcl | 19 | $247 |
| Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril | 12 | $154 |
| Pravastatin Sodium | 14 | $152 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $91,366 | $1,520,482365 claims |
| Viiv Healthcare CompanyDovato, Triumeq, Tivicay | $97,448 | $367,236127 claims |
| Janssen Products, LPSymtuza | $540 | $93,40220 claims |
| Johnson & JohnsonPrezcobix | $621 | $61,12320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 289 infectious disease providers in Maryland.
Other infectious disease in Silver Spring
- Michael KorenSilver Spring$206K
- John BeigelBethesda$15M
- Mohamed Al IbrahimBaltimore$4.9M
- Kawsar TalaatBaltimore$4.2M
- David McDermottBethesda$3.2M
- Amy KlionBethesda$2.8M
- Joel ChuaBaltimore$2.4M
- Timothy BurgessBethesda$2.2M
- Namrata ShahGreenbelt$2.1M
- Bret PurcellFrederick$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.